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ABSTRACT
The pharmacokinetics, urinary excretion and dosage regimen of cefotaxime after its single intravenous 
administration (10 mg/kg) was investigated in experimentally induced fever in buffalo calves (n = 5). The fever 
was induced by intravenous injection of E. coli lipopolysaccaride (1 µg/kg). At 1 min. the concentration of 
cefotaxime in plasma was 90.9 ± 2.85 µg/mL, which rapidly declined to 26.2 ± 1.05 µg/mL at 10 min. The drug 
was detected for up to 8 h. The elimination half-life and volume of distribution were 1.85 ± 0.11 hr and 1.70 ± 
0.07 L/kg, respectively. The distribution half-life and area under curve (AUC) were 0.078 ± 0.003 hr and 15.8 ± 
0.85 µg/mL.hr, respectively. Total body clearance (Cl
B
) and tissue/plasma (T/C) ratio were 644 ± 39.2 mL/kg/h 
and 15.8 ± 1.04, respectively. Cefotaxime was bound to plasma proteins of febrile buffalo calves to the extent of 
32.3 ± 1.86 per cent. To maintain a minimum therapeutic concentration of 1 µg/mL, a satisfactory dosage regimen 
of cefotaxime in febrile buffalo calves would be 17 mg/kg, followed by 15 mg/kg at 6 h. intervals.
Key words: buffalo calf, cefotaxime, dosage regimen, fever, pharmacokinetics, protein binding, urinary 
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Introduction
Cefotaxime, a semisynthetic bactericidal cephalosporin, is effective against a wide variety 
of Gram-positive and Gram-negative microorganisms (NEU et al., 1979). Pharmacokinetics 
of chemotherapeutic agents are markedly altered in disease conditions (LESAR and ZASKE, 
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1984; HARY et al., 1989; TOTH et al., 1991; SINGH et al., 1998; CHAUDHARY et al., 1999; 
DARDI et al., 2005; SHARMA et al., 2005). Hence, the dosage regimen obtained in healthy 
subjects cannot be extrapolated in clinical cases to treat diseased animals. Fever, which is 
one of the most common manifestations of many infectious diseases, is reported to induce 
a series of biochemical and physiological alterations in cells (VAN MIERT, 1985 and 1987; 
LOHUIS et al., 1988). Therefore, a study on the influence of fever on the pharmacokinetics 
of antibiotics is essential. The aim of this study was to determine the disposition kinetic 
variables of cefotaxime and its urinary excretion in febrile buffalo calves following 
intravenous administration. From the disposition kinetic data, recommendations were 
made for optimal dosage regimens of cefotaxime in febrile buffalo calves. 
Materials and methods
The experiment was performed on five healthy male buffalo calves of 6-12 months 
of age, weighing an average of 98 kg. The animals were housed in the departmental 
shed that had a concrete floor and were provided green fodder and water ad libitum. 
Each animal was quarantined for two weeks before the start of experiment and was 
determined to be healthy by regular clinical examination. Fever was induced by 
intravenous administration of E. coli lipopolysaccaride at a dose rate of 1 µg/kg b.wt 
as standardized in our previous study (SHARMA et al., 1996) in buffalo calves. This dose 
of lipopolysaccaride caused fever within two h., and fever persisted for 4-6 h. At least a 
1.1 0C increase of temperature from normal temperature was taken as the time of cefotaxime 
administration. Once fever was induced, cefotaxime sodium was injected intravenously to 
these five animals at a dose rate of 10 mg/kg of cefotaxime, in a 10% solution with sterilized 
distilled water. Blood samples (5 mL each) were withdrawn from the contralateral jugular 
vein into heparanized glass test tubes before administration and at 1, 2.5, 5, 7.5, 10, 15, 30, 
45, 60, and 90 min. and 2, 3, 4, 5, 6, 7 and 8 h. after administration of drug. Plasma was 
collected after centrifugation at 2000 g for 15 min. at room temperature and kept at -20 0C 
until analysis, usually occurring the next day. Concentration of cefotaxime in plasma was 
estimated by employing the microbiological assay technique (ARRET et al., 1971) using 
Escherichia coli (ATCC 25922) as the test organism. This method does not distinguish 
between activity of the parent compound and its metabolites.
The assay could detect a minimum of 0.1 µg/mL of cefotaxime. The standard curve of 
cefotaxime in calf plasma was linear, between 0.25 and 1.25 µg/mL. The reproducibility 
of this method was excellent and error within day estimation was less than 5%. Each 
sample was diluted to the extent that its zone of inhibition came in linear range (preferably 
in the range of the zone of inhibition of the reference concentration). In this experiment 
the reference concentration was 0.5 µg/mL. The plasma concentration-time data for each 
buffalo calf were determined according to the computed least squares regression technique. 
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Kinetic parameters were calculated from the formulae derived for a two-compartment open 
model (NOTARI, 1980; GIBALDI and PERRIER, 1982). 
The dosage regimen of cefotaxime was also determined based on the kinetic data. The 
priming (D) and maintenance (D
1














Table 1. Disposition kinetic parameters of cefotaxime in febrile buffalo calves (n = 5) after a 
single intravenous injection of 10 mg/kg body mass
Parametera Unit Mean ± SE
Co
p
µg/mL 98.5 ± 3.41
A µg/mL 96.7 ± 3.44
B µg/mL 1.84 ± 0.11
α /h 8.95 ± 0.36
β /h 0.381 ± 0.026
t
1/2α h 0.078 ± 0.003
t
1/2β h 1.85 ± 0.11
K
12
/h 2.48 ± 0.08
K
21
/h 0.54 ± 0.03
K
12/K21
 ratio - 4.65 ± 0.31
AUC µg/mL.h 15.8 ± 0.85
V
d(area )
L/kg 1.70 ± 0.07
Cl
B
mL/kg/h 644 ± 39.2
T/P ratio - 15.8 ± 1.04
t
d
h 10.4 ± 0.63
a Kinetic parameters as described by GIBALDI and PERRIER (1982). Cop = Plasma drug concentra-
tion immediately following intravenous injection of a single dose; A, B
 
= zero-time plasma drug 
concentration intercepts of regression lines of distribution and elimination phases, respectively;
 
α 
and β = distribution and elimination rate constants, respectively; t
1/2α = distribution half life; t1/2β = 




 = rate of transfer of drug from central (blood) to peripheral (tissues) 
compartment and vice-versa; AUC = total area under plasma drug concentration-time curve; Vd(area) 
= apparent volume of distribution; Cl
B
 = total plasma clearance; T/P = tissue /plasma ratio of drug 
concentration; t
d
 = duration of therapeutic plasma concentration.
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Fig 1. A semi-logarithmic plot of plasma levels of cefotaxime after a single intravenous dose of 
10 mg/kg b. wt. in febrile buffalo calves. Values given are mean ± SE of 5 animals. SE shown at 
8 h. is one-third of actual SE. Data were analysed according to two-compartment open model. The 
calculated points (O) of the distribution phase are obtained by feathering techniques.
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Discussion
Evaluation of results on plasma cefotaxime levels against time indicated that 
pharmacokinetics of cefotaxime in febrile buffalo calves, after intravenous administration, 
was best described by the two-compartment open model. The plasma concentration-time 
data were adequately described by the equation: 
C 
p
 = Ae-αt + Be-βt 
Where Cp is cefotaxime concentration in plasma at time ‘t’. A and B are zero time 
intercepts of the distribution and elimination phase of the plasma concentration time curve. 
α and β are the distribution and elimination rate constants, respectively, and ‘e’ represents 
the base of natural logarithm.
Table 2. Calculated intravenous dosage regimen of cefotaxime required to maintain specified 









0.2 6 3.34 3.00
0.2 8 7.16 6.82
0.4 6 6.68 6.00
0.4 8 14.3 13.6
0.6 6 10.0 9.00
0.6 8 21.5 20.5
0.8 6 13.4 12.0
0.8 8 28.6 27.3
1.0 6 16.7 15.0
1.0 8 35.8 34.1
The mean plasma concentration of cefotaxime as a function of time was plotted on 
a semilogarithmic scale (Fig.1). At 1 min. the mean plasma concentration of cefotaxime 
was 90.9 ± 2.85 µg/mL, which rapidly declined to plasma concentration of 26.2 ± 1.05 
µg/mL at 10 min. Levels then gradually decreased to 0.03 ± 0.03 µg/mL at 8 h. Various 
pharmacokinetic parameters for cefotaxime in buffalo calves in which fever was induced 
before administration of drug are presented in Table 1. Taking 6 and 8h. as convenient 
dosage intervals (τ) with minimum therapeutic concentration C
p 
(min)α of 0.2, 0.4, 0.6, 
0.8 and 1.0 µg/mL and using the values of β and V
d (area) 
of Table 1, the dosage regimen of 
cefotaxime were computed and are presented in Table 2.
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Cefotaxime after intravenous administration has also been reported to follow the two-
compartment open model in dogs (GUERRINI et al., 1986), goats (ATEF et al., 1990) and 
in healthy buffalo calves (SHARMA, 2000). A comparison of plasma levels of cefotaxime 
in febrile animals with healthy animals (SHARMA, 2000) indicates that the peak plasma 
levels of cefotaxime in febrile buffalo calves (90.9 ± 2.85 µg/mL ) was higher than healthy 
buffalo calves (71.8 ± 2.49 µg/mL ), but generally most of the time the plasma concentration 
in febrile buffalo calves was similar to healthy animals. The high values of distribution 
rate constant α (8.95 ± 0.36 /h) indicate that cefotaxime is rapidly distributed into various 
body fluids and tissue compartments. The rapid distribution of cefotaxime is further 




 (4.65 ± 0.31). The values of V
d(area) 
of cefotaxime 
in healthy animals (SHARMA, 2000) is lower (1.17 ± 0.10 L/kg)
 
as compared to febrile 
animals (1.70 ± 0.07 L/kg)
. 
In accordance with our present findings, CHAUDHARY et al. 
(1999) reported an increase in V
d(area) 
of cefuroxime in febrile buffalo calves as compared 
to healthy subjects .
While comparing total body clearance in febrile animals with that of healthy animals 
(SHARMA, 2000), it was found that the value of Cl
B
 in febrile animals (644 ± 39.2 mL/kg/h) 
is not significantly different when compared to healthy animals (675.2 ± 38.7 mL/kg/h). 
Endotoxin causes hepatic, renal dysfunctions (WILKINSON et al. 1974; WILKINSON, 1977) as 
well as haemodynamic depression (VAN MIERT, 1973). The depressing effect of endotoxin 
on the renal system could have contributed to the change in volume of distribution in febrile 
animals. Because of significant alterations in hepatic function the levels of various enzymes, 
responsible for the metabolism of these antimicrobials, is altered, changing the elimination 
and biotransformation pattern of the drug during fever (SINGH et al., 1997).
At the end of 24 h., urinary excretion was 4% of total administered dose (Table 2), which 
was similar to that of healthy buffalo calves (SHARMA, 2000). In healthy crossbred calves, 
following a single intravenous administration of cefotaxime (10 mg/kg) approximately 4.5% 
of drug was recovered in urine within 12 h. (SHARMA et al., 1995). TOTH et al. (1991) have 
also reported that the fraction of the administered dose of ceftriaxone excreted in urine of 
liver transplant recipients did not differ markedly from that of normal subjects. 
The extent of binding of cefotaxime to plasma protein of febrile buffalo calves was 
32.3 ± 1.86 per cent. Similarly, cefotaxime was reported to bind plasma proteins of human 
(NEU, 1982) and crossbred calves (SHARMA and SRIVASTAVA, 1994) to the extent of 
36-40 and 30.2 per cent, respectively. However, it may be inferred that the binding of 
cefotaxime to plasma protein is weak in buffalo calves, which is evident from the low 
value of β
i
 and that it is reversible from the high value of the dissociation rate constant for 
the protein-drug complex. 
The ultimate aim of the present study was to determine a satisfactory dosage regimen 
in febrile buffalo calves. It is not axiomatic to compute the dosage regimen of cefotaxime 
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to be used effectively in clinical practice for the treatment of mild to severe bacterial 
infections, without having first conducted a detailed pharmacokinetic study. With a 
minimum therapeutic plasma concentration of cefotaxime as 1.0 µg/mL (KNUDSEN et 
al., 1997), which has been shown to be most effective against the majority of sensitive 
Gram-positive and Gram-negative pathogens, the convenient and suitable dosage regimen 
of cefotaxime in the febrile buffalo calves after intravenous administration would be 17 
mg/kg followed by 15 mg/kg at 6 h. intervals.
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SAŽETAK
Farmakokinetika, izlučivanje mokraćom i režim doziranja cefotaksima nakon njegova jednokratnoga 
intravenskoga unosa (10 mg/kg) istraženi su u bivolje teladi (n = 5) s pokusno uzrokovanom vrućicom. Vrućica 
je bila uzrokovana ubrizgavanjem lipopolisaharida bakterije E. coli u količini 1 µg/kg. Koncentracija cefotaksima 
u plazmi nakon jedne minute bila je 90,9 ± 2,85 µg/mL te se brzo spustila na 26,2 ± 1,05 µg/mL u 10. minuti. 
Lijek se mogao dokazati do osam sati nakon davanja. Poluvrijeme njegova izlučivanja iznosilo je 1,85 ± 0,11 
sati, a volumen raspodjele 1,70 ± 0,07 L/kg. Poluvrijeme raspodjele bilo je 0,078 ± 0,003 sati, dok je površina 
ispod koncentracijske krivulje bila 15,8 ± 0,85 µg/mL/sat. Ukupni tjelesni klirens bio je 644 ± 39,2 mL/kg/sat, a 
omjer tkivo/plazma bio je 15,8 ± 1,04. Cefotaksim je bio vezan na bjelančevine plazme u febrilne bivolje teladi 
do 32,3 ± 1,86%. Za održavanje minimalne terapijske koncentracije cefotaksima od 1 µg/mL u febrilne bivolje 
teladi dostatna je početna doza od 17 mg/kg, a nakon toga slijede doze od 15 mg/kg u razmacima od šest sati.
Ključne riječi: bivolja telad, cefotaksim, doziranje, vrućica, farmakokinetika, vezanje na bjelančevine, 
izlučivanje u mokraći
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